Skip to main content

Table 3 Multivariate analysis on predictive factors for mortality

From: Survival and predictive factors in dialysis patients with COVID-19 in Japan: a nationwide cohort study

  Hazard ratio 95% confidence interval of hazard ratio p value
Lower limit Upper limit
Age (reference: < 60)
 60 s 1.58 0.90 2.77 0.109
  ≥ 70 4.92 3.10 7.80 < 0.001
Gender (reference: male) 0.82 0.60 1.11 0.202
Primary disease (reference: chronic glomerulonephritis)
 Diabetes mellitus 1.16 0.46 2.95 0.751
 Nephrosclerosis 0.94 0.55 1.61 0.829
 Others 1.56 0.91 2.68 0.106
Duration of dialysis (reference: < 1 year)
 1 to < 5 years 2.07 1.21 3.53 0.008
 5 to < 10 years 2.00 1.16 3.45 0.013
 10 to < 15 years 2.69 1.49 4.85 0.001
 ≥ 15 years 2.68 1.48 4.88 0.001
Complication
 Diabetes mellitus 1.12 0.45 2.77 0.813
 Hypertension 0.87 0.65 1.16 0.337
 Cardiovascular disease 1.25 0.94 1.68 0.130
 Chronic respiratory disease 0.87 0.55 1.38 0.561
 Peripheral arterial disease 1.49 1.05 2.10 0.025
 Malignancy 0.91 0.62 1.33 0.626
Oxygenation (reference: no oxygenation)
 Oxygen supplementation 3.44 2.06 5.73 < 0.001
 Ventilator or ECMO 6.72 3.86 11.69 < 0.001
Remdesivir (reference: without remdesivir) 0.60 0.37 0.98 0.041
Dexamethasone (Reference: without dexamethasone) 1.36 1.01 1.83 0.040
  1. Multivariate analysis was performed, with incidence of COVID-19 in facilities (less than 5 or more than 5), age (< 60, 60 s, ≥ 70), gender, primary disease (chronic glomerulonephritis, diabetes mellitus, nephrosclerosis, or others), duration of dialysis (< 1 year, 1 to < 5 years, 5 to < 10 years, 10 to < 15 years, or ≥ 15 years), complications (diabetes mellitus, hypertension, cardiovascular disease, peripheral arterial disease, or malignancy), oxygenation (with or without oxygen supplementation, ventilator, or ECMO), treatment for COVID-19 (with or without remdesivir or dexamethasone) as independent variables
  2. ECMO extracorporeal membrane oxygenation